小牛脾提取物辅助化疗对中晚期胃癌患者肿瘤负荷和免疫功能的影响
| 作者: |
1蔡培培,
1祁永军,
1缪敏
1 江都人民医院肿瘤内科，江苏 扬州 225200 |
| 通讯: |
蔡培培
Email: caipeipei121@163.com |
| DOI: | 10.3978/j.issn.2095-6959.2019.06.008 |
摘要
目的：探讨小牛脾提取物辅助化学药物治疗(以下简称化疗)对中晚期胃癌患者肿瘤负荷和免疫功能的影响及不良反应评估。方法：选取2014年1月至2016年9月扬州市江都人民医院收治的中晚期胃癌患者82例，随机分为观察组和对照组，各41例。对照组应用FOLFOX4方案化疗，观察组在此基础上使用小牛脾提取物治疗。于治疗前后比较两组肿瘤负荷、免疫因子水平的差异，并观察两组临床疗效、不良反应及预后情况。结果：观察组缓解率为68.29%，显著高于对照组的39.02%，差异有统计学意义(χ2=7.062，P=0.008)。观察组治疗后CD3+，CD4+，CD8+，CD4+/CD8+水平与治疗前比较，差异均无统计学意义(均P>0.05)；对照组治疗后CD3+，CD4+，CD4+/CD8+水平均显著低于治疗前，且均显著低于观察组治疗后水平，CD8+明显高于治疗前，且高于观察组治疗后水平，差异均有统计学意义(均P<0.05)。治疗后，两组TK1，Cyclin D1，angiopoietin-2和pentraxin-3水平均显著低于治疗前(均P<0.01)；且观察组各肿瘤负荷因子水平较对照组下降程度更显著(均P<0.01)。观察组总不良反应发生率为36.59%，显著低于对照组的63.41%，差异有统计学意义(χ2=7.062，P=0.008)。观察组2年生存率为51.22%，显著高于对照组的34.15%，差异有统计学意义(χ2=5.342，P=0.021)。结论：小牛脾提取物可改善中晚期胃癌化疗患者的免疫功能，减轻患者的肿瘤负荷，减少不良反应的发生，延长患者的生存时间。
关键词：
小牛脾提取物；胃癌；肿瘤负荷；免疫功能；不良反应
Effect of calf spleen extract adjuvant chemotherapy on tumor burden and immune function in patients with advanced gastric cancer
CorrespondingAuthor: CAI Peipei Email: caipeipei121@163.com
DOI: 10.3978/j.issn.2095-6959.2019.06.008
Abstract
Objective: To investigate the effect of calf spleen extract adjuvant chemotherapy on tumor burden, immune function and adverse reactions in patients with advanced gastric cancer. Methods: Eighty-two cases of advanced gastric cancer patients admitted to our hospital from January 2014 to September 2016. They were randomly divided into an observation group and a control group, 41 cases in each. Patients in the control group were treated with FOLFOX4 regimen, and patients in the observation group were treated with calf spleen extract. The differences of tumor burden and immune factor levels between the two groups were compared before and after treatment, and the clinical efficacy, adverse reactions and prognosis of the two groups were observed. Results: The response rate of the observation group was 68.29%, which was significantly higher than that of the control group (39.02%). The levels of CD3+, CD4+, CD8+, and CD4+/CD8+ in the observation group were significantly lower than those before treatment (all P>0.05). The levels of CD3+, CD4+, and CD4+/CD8+ in the control group were significantly lower than those before treatment and also lower than those in the observation group (P<0.05). CD8+ level was significantly higher after the treatment than before the treatment, and higher than the post-treatment level in the observation group (P<0.05). After the treatment, the levels of TK1, Cyclin D1, angiopoietin-2 and pentraxin-3 in the two groups were significantly lower than those before the treatment (P<0.01). The level of tumor load factor in the observation group was more significant than the control group (P<0.01). The overall adverse reaction rate was 36.59% in the observation group, which was significantly lower than the 63.41% in the control group (χ2=7.062, P=0.008). The 2-year survival rate of the observation group was 51.22%, which was significantly higher than that of the control group (34.15%, χ2=5.342, P=0.021). Conclusion: Calf spleen extract can improve the immune function in patients with advanced gastric cancer chemotherapy, reduce the tumor burden of patients, reduce the occurrence of adverse reactions, and prolong the survival time of patients.
Keywords：
calf spleen extract; gastric cancer; tumor burden; immune function; adverse reactions